Cancer Medicines & Molecular Diagnostics

Pair established cancer-drug franchises with molecular diagnostics and the laboratory platforms supporting precision oncology. Lilly's latest franchise milestone highlights the capacity of successful drugmakers to fund further pipeline development, although that headline concerns metabolic medicines rather than an oncology breakthrough. This basket targets cancer treatment and testing rather than broad healthcare defensiveness; clinical setbacks, reimbursement pressure and research-budget weakness remain risks. Catalysts: - 2026-10-15 LLY: GLP-1s took Eli Lilly to a $1 trillion market cap; CEO bets billions on further pipeline development (https://www.forbes.com/sites/amyfeldman/2026/10/15/glp-1s-took-eli-lilly-to-1-trillion-ceo-dave-ricks-is-betting-billions-he-can-do-it-again/) Launch basket (equal weight): MRK, ABBV, AMGN, LLY, DHR, BMY, REGN, NTRA, GH, ILMN Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.